Regeneron Pharmaceuticals, Inc. (REGN) — Not yet assessed · Company page | HillSignal
Verified IDREGN · Nasdaq
Regeneron Pharmaceuticals, Inc.
Biopharmaceutical development and manufacturing.
Company page · Records as of 17 Nov 2026
Federal contracts
$279M
Last 12 months, committed, not revenue
Federal commitments vs revenue
1.7%
Committed ÷ revenue, 12 months; not a revenue split
Contracts ending in 18 months
$279M
1 contract · lifetime money, not revenue at risk
Money
Revenue and federal contracts, by year
Contracts obligated, federal fiscal yearCompany revenue, its fiscal year ending that year (10-K)
FY2026$279M$14.3B
FY2025$-331708160$14.2B
FY2024$-1435528$13.1B
FY2023$326M$12.2B
FY2022$494K$16.1B
Committed contract money is not revenue: a multi-year contract can be funded in one year. Prime contracts only; subcontracts and classified work are not included.
Who pays, fiscal 2026
Health and Human Services$279M
Ending within 18 months1 contract · $279M full value
25 Sep 2027$279M Office of Assistant Secretary for Preparedness and Response contract: - regeneron other transaction authority (OTA) award1 offer last time · Regeneron Pharmaceuticals Inc · Source
Largest current contracts
$974MOffice of Assistant Secretary for Preparedness and Response contractOffice of Assistant Secretary for Preparedness and Response · runs to 29 Sep 2031 · Regeneron Pharmaceuticals Inc · Source
$279M- regeneron other transaction authority (OTA) awardOffice of Assistant Secretary for Preparedness and Response · runs to 25 Sep 2027 · Regeneron Pharmaceuticals Inc · Source
By industryLargest: Research and development in biotechnology, $279M · 12m
$279MResearch and development in biotechnology3 contracts with money in the last 12 months · industry code 541711
Federal contract money committed in the last 12 months, by each contract's industry code. Committed money is not revenue.
Developments
What's developing1 development · Top: Biodefense / Pandemic Preparedness
Influence
Lobbying
Filings
62
Latest year
2026
Issues
Budget/Appropriations
Copyright/Patent/Trademark
Health Issues
Medicare/Medicaid
Taxation/Internal Revenue Code
Trade (domestic/foreign)
Lobbyists who held government posts
Steven CraneStaff assistant, Sen. Barbara Mikulski
Zachary Austin PriceStaff assistant to Sen. Coats
Gregory NickersonTax Counsel, Ways and Means CommitteeStaff Director, Ways and Means Select Revenue Measures Subcommittee
Raghav AggarwalHealth Insurance Specialist, CMSSenior Health Advisor (Detailee), Senate Finance Committee/Sen. Ron Wyden+3 more postsHealth Insurance Specialist, CMSSenior Health Advisor (Detailee), Senate Finance Committee/Sen. Ron WydenSocial Science Research Analyst, CMSIntern, Sen. FeinsteinSecretarys Fellow, US Dept. of Interior
Brent Alan Del MonteLeg. Dir. Rep. Bliley
People
Key people
Christine A. PoonDirector
Michael S. BrownDirector
Andrew J. MurphyCo-Chief Scientific Officer
Marion McCourtEVP Commercial
Kathryn GuariniDirector
Joseph J. LarosaEVP General Counsel and Secret
Christopher R. FenimoreEVP Finance CFO
Arthur F. RyanDirector
Huda Y. ZoghbiDirector
Jason PitofskySVP Controller
Bonnie L. BasslerDirector
David P. SchenkeinDirector
George L. SingDirector
Joseph L. GoldsteinDirector
Craig B. ThompsonDirector
Connections
Disclosed tradeRo KhannaRohit Khanna disclosed a purchase in REGN
$6.3MJason Pitofsky, SVP Controller: sold4 Nov 2026 · Source
$10.1MHuda Y. Zoghbi, Director: sold3 Nov 2026 · Source
$10.5MChristine A. Poon, Director: sold2 Nov 2026 · Source
$26.2MGeorge L. Sing, Director: sold2 Nov 2026 · Source
$648KKathryn Guarini, Director: sold30 Oct 2026 · Source
$3.1MMichael S. Brown, Director: sold30 Oct 2026 · Source
Congressional trades
7 Jul 2026
Activity
Patents (5 on file)
29 Sep 2026Methods and Antibody Compositions for Tumor TreatmentUS 12747300
15 Sep 2026METHODS OF TREATING AN INTERLEUKIN-2 RECEPTOR GAMMA-MEDIATED DISEASE OR CONDITION BY ADMINISTERING AN IL2 RECEPTOR GAMMA ANTIBODYUS 12735496
1 Sep 2026Anti-CD45 Antibody Drug Conjugates and Uses ThereofUS 12723097
25 Aug 2026RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOFUS 12715881
11 Aug 2026METHODS FOR TREATING CHRONIC RHINOSINUSITIS WITH NASAL POLYPS BY ADMINISTERING AN ANTIBODY ANTAGONIST OF IL-4RUS 12702709
From a USPTO sample of recent grants in strategic technology areas, not a full patent database: a missing patent here is not proof there is none.
Sources
Where the records come from
Federal contracts
USAspending award records (fiscal 2025 onward), linked by contractor ID
Purchase notices
SAM.gov
Lobbying
Senate Lobbying Disclosure Act filings
Political giving
Federal Election Commission (FEC)
Insider trades
SEC Form 4
Revenue
SEC filings (10-K, 10-Q)
Private raises
SEC Form D
Patents
USPTO, a sample of recent grants in strategic technology areas
Congressional trades
House and Senate financial disclosures
Every record on this page links to its source.
Committed contract money is not revenue.
Records as of 17 Nov 2026; revenue for the 12 months to Sep 2026.
Ask Intel
Source-backed
Sen. Counsel House Energy & Commerce Committee
Remy Leigh Brim MasonSenior FDA Policy Advisor to Senate HELP Committee Ranking Member Patty MurraySenior Health Policy Advisor Sen. Elizabeth Warren+1 more postSenior FDA Policy Advisor to Senate HELP Committee Ranking Member Patty MurraySenior Health Policy Advisor Sen. Elizabeth WarrenIntern to Rep. Allyson Schwartz
Daniel FarmerIntern, Staff Asst, Leg. Corr./Leg. Asst. for Rep. Debbie Wasserman SchultzLeg. Asst., Sr. Leg. Asst., Leg. Dir. for Zack Space
John StoneCounsel, House E&C Cmte, Oversight SubcommitteeSenior Counsel, House E&C Cmte, Health Subcommittee+1 more postCounsel, House E&C Cmte, Oversight SubcommitteeSenior Counsel, House E&C Cmte, Health SubcommitteeIntern, House E&C
Timothy Lucas BlanchatChief of Staff, Congressman Richard HudsonDeputy State Director, Sen. Thom Tillis
Sam HollandDepartment of TreasuryNational Security Council
Frederick VaughanPrincipal Deputy Asst. Secretary, Treasury DeptDeputy Asst. Secretary, Treasury Dept+4 more postsPrincipal Deputy Asst. Secretary, Treasury DeptDeputy Asst. Secretary, Treasury DeptSenior Counsel, House Financial Services CmteAssociate Director, The White HouseConfidential Asst., Office of Management & BudgetWriter, The White House
Dean Phillips disclosed a sale_partial in REGN
Disclosed tradeGreg LandsmanGreg Landsman disclosed a purchase in REGN
Disclosed tradeDonald Sternoff BeyerDonald Sternoff Beyer disclosed a purchase in REGN
Shared personRoyalty Pharma plc ($RPRX)Bassler Bonnie L is Director at one entity and Director at the other
Disclosed tradeRob BresnahanRob Bresnahan disclosed a sale in REGN
Disclosed tradeGilbert CisnerosGilbert Cisneros disclosed a purchase in REGN
Disclosed tradeJosh GottheimerJosh Gottheimer disclosed a sale in REGN
Disclosed tradeTommy TubervilleTommy Tuberville disclosed a purchase in REGN
Disclosed tradeSheldon WhitehouseSheldon Whitehouse disclosed a purchase in REGN
Disclosed tradeJulie JohnsonJulie Johnson disclosed a sale in REGN
Disclosed tradeJonathan JacksonJonathan Jackson disclosed a sale in REGN
Disclosed tradeMikie SherrillMikie Sherrill disclosed a sale in REGN
Fund holder and contractHunter Perkins Capital ManagementHunter Perkins Capital Management disclosed a $0.0M position in REGENERON PHARMACEUTICALS ($REGN) in its 2026-06-30 13F filing. REGENERON PHARMACEUTICALS INC was separately awarded a $973.6M contract by Department of Health and Human Services.
Rohit Khanna, House: bought$1,001 to $15,000
15 May 2026Gilbert Cisneros, House: sold$1,001 to $15,000
13 Apr 2026Ro Khanna, House: bought$1,001 to $15,000
13 Apr 2026Rohit Khanna, House: sold$1,001 to $15,000
27 Mar 2026Alan Armstrong, Senate: bought$1,001 to $15,000
12 Feb 2026Julia Letlow, House: bought$1,001 to $15,000